Japanese Government Considers Granting Patents To Medical Applications Using iPS Cells
This article was originally published in PharmAsia News
The Japanese government is considering starting a review process on granting patents to medical applications using induced pluripotent stem cells. The Intellectual Property Strategy Council, a cabinet level agency led by Prime Minister Yasuo Fukuda, made the announcement April 17. The review process could start as early as June. Facing increasing international competition on granting patents to iPS cell technology, the government wants to start the process earlier. Currently, medical applications using iPS cells are patented in the U.S., and Japanese regenerative medicine researchers have been concerned that without patents, Japanese regenerative medicine will lose out to American counterparts. (Click here for more-Japanese language
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.